EndLyz Therapeutics develops new drugs designed to restore endolysosomal function in order to combat neurodegeneration in Parkinson’s disease and other forms of dementia. The company focuses on two crucial lysosomal transport proteins, ATP13A2 and ATP10B, which are responsible for transporting lipids across cellular membranes. When these proteins do not function properly, lysosomal function is disrupted—a mechanism linked to neurological disorders.
Investors 1
Mentions in press and media 1
Reviews 0
